Istituto Nazionale per le Malattie Infettive Lazzaro Spallanzani
- Web page: http://www.inmi.it/
- Country: Italy
- project . 2015 - 2017Funder: EC Project Code: 115844Overall Budget: 2,260,100 EURFunder Contribution: 2,260,100 EUROpen Access mandate for PublicationsPartners: GNA BIOSOLUTIONS GMBH, Mendelova univerzita v Brne, Istituto Nazionale per le Malattie Infettive Lazzaro Spallanzani, EMERGENCY ONG ONLUS
There is an urgent need for fast and accurate diagnostic tests in the current Ebola crisis. The rapid diagnosis of EVD during early and late stage of infection is a decisive step for risk assessment and for guidance to physicians to take the necessary decisions to limit...
- project . 2020 - 2022Funder: EC Project Code: 101003544Overall Budget: 2,547,150 EURFunder Contribution: 2,547,150 EUROpen Access mandate for PublicationsPartners: UB, AMU, ICN2, Istituto Nazionale per le Malattie Infettive Lazzaro Spallanzani
The recent outbreak in China caused by the emerging nCoV virus is challenging the level of global readiness from governments, public organizations and community to face and manage both its social and health consequences. Once the emergence is recognized and identified, ...
- project . 2020 - 2024Funder: EC Project Code: 101005111Overall Budget: 3,747,600 EURFunder Contribution: 3,435,100 EUROpen Access mandate for PublicationsPartners: BMVg, MicroLIQUID (Spain), ARC, GNA BIOSOLUTIONS GMBH, Istituto Nazionale per le Malattie Infettive Lazzaro Spallanzani
The DECISION consortium is developing a new class of diagnostic platform that will transform the fight against pandemics. The low-cost, miniaturised, disposable molecular diagnostic platform will allow for patient testing virtually anywhere, within a few minutes, with l...
- project . 2020 - 2022Funder: EC Project Code: 101005075Overall Budget: 1,819,960 EURFunder Contribution: 784,470 EUROpen Access mandate for PublicationsPartners: BIOTRONICS LTD, UNIVERSITA DI CORSICA PASQUALE PAOLI, AMU, BG Research Ltd, Istituto Nazionale per le Malattie Infettive Lazzaro Spallanzani
This project focuses on rapid (40min), simple, Point-of-Need COVID-19 testing, e.g. surgery/home (via first responders)/transit points of entry. BG Research (BGR) has developed direct from crude sample detection of viral pathogens – the QuRapID-XF technology, removing r...
- project . 2015 - 2017Funder: EC Project Code: 115848Overall Budget: 4,398,250 EURFunder Contribution: 1,162,620 EUROpen Access mandate for PublicationsPartners: BNI, Alere (Germany), DH, FIND, Istituto Nazionale per le Malattie Infettive Lazzaro Spallanzani, ALTONA
We are proposing to develop a molecular assay for the safe, rapid, specific and sensitive detection of Ebola Virus Infection in capillary (or venous) blood samples combining ALTONA’s Pan-filo screening IVD test with the existing Alere™ q point of care molecular diagnost...